News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Johnson & Johnson Sells U.S. Rights to St. Joseph’s Asprin for Undisclosed Sum
January 7, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WSJ -- Johnson & Johnson sold its St. Joseph's aspirin brand to a closely held Baltimore company for an undisclosed sum, the companies said Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Deals
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
December 18, 2025
·
1 min read
·
BioSpace Insights
influenza
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine
December 18, 2025
·
1 min read
·
Dan Samorodnitsky
Collaboration
GSK Makes $400M+ RNA Play With CAMP4 Collab, Targets Neuro, Kidney Diseases
December 18, 2025
·
1 min read
·
Tristan Manalac
China
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour
December 17, 2025
·
1 min read
·
Tristan Manalac
